Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (84)

May 19, 2043method-of-use (U-3754)US 11872211
May 19, 2043method-of-use (U-3754)US 11872211
May 19, 2043method-of-use (U-3754)US 11872211
May 19, 2043method-of-use (U-3754)US 11925619
May 19, 2043method-of-use (U-3754)US 11925619
May 19, 2043method-of-use (U-3754)US 11925619
May 19, 2043method-of-use (U-3754)US 11925620
May 19, 2043method-of-use (U-3754)US 11925620
May 19, 2043method-of-use (U-3754)US 11925620
May 19, 2043method-of-use (U-3754)US 11938116
May 19, 2043method-of-use (U-3754)US 11938116
May 19, 2043method-of-use (U-3754)US 11938116
May 19, 2043method-of-use (U-3754)US 11951096
May 19, 2043method-of-use (U-3754)US 11951096
May 19, 2043method-of-use (U-3754)US 11951096
May 19, 2043method-of-use (U-3754)US 11957662
May 19, 2043method-of-use (U-3754)US 11957662
May 19, 2043method-of-use (U-3754)US 11957662
May 19, 2043method-of-use (U-3754)US 12011434
May 19, 2043method-of-use (U-3754)US 12011434
May 19, 2043method-of-use (U-3754)US 12011434
May 19, 2043method-of-use (U-3754)US 12011435
May 19, 2043method-of-use (U-3754)US 12011435
May 19, 2043method-of-use (U-3754)US 12011435
May 19, 2043method-of-use (U-3754)US 12036207
May 19, 2043method-of-use (U-3754)US 12036207
May 19, 2043method-of-use (U-3754)US 12036207
May 19, 2043method-of-use (U-3754)US 12138246
May 19, 2043method-of-use (U-3754)US 12138246
May 19, 2043method-of-use (U-3754)US 12138246
Sep 8, 2042formulationUS 11807611
Sep 8, 2042formulationUS 11807611
Sep 8, 2042formulationUS 11807611
Sep 8, 2042formulationUS 11844780
Sep 8, 2042formulationUS 11844780
Sep 8, 2042formulationUS 11844780
Jul 8, 2042formulationUS 11504354
Jul 8, 2042formulationUS 11504354
Jul 8, 2042formulationUS 11504354
Jul 8, 2042formulationUS 11612588
Jul 8, 2042formulationUS 11612588
Jul 8, 2042formulationUS 11612588
Jul 8, 2042formulationUS 12110277
Jul 8, 2042formulationUS 12110277
Jul 8, 2042formulationUS 12110277
Jul 8, 2042formulationUS 12234210
Jul 8, 2042formulationUS 12234210
Jul 8, 2042formulationUS 12234210
Jul 8, 2042formulationUS 12247012
Jul 8, 2042formulationUS 12247012
Jul 8, 2042formulationUS 12247012
Aug 9, 2039compositionUS 10590087
Aug 9, 2039compositionUS 10590087
Aug 9, 2039compositionUS 10590087
Aug 9, 2039compositionUS 10710966
Aug 9, 2039compositionUS 10710966
Aug 9, 2039compositionUS 10710966
Aug 9, 2039compositionUS 10941118
Aug 9, 2039compositionUS 10941118
Aug 9, 2039compositionUS 10941118
Aug 9, 2039formulationUS 11820748
Aug 9, 2039formulationUS 11820748
Aug 9, 2039formulationUS 11820748
Aug 9, 2039compositionUS 11845732
Aug 9, 2039compositionUS 11845732
Aug 9, 2039compositionUS 11845732
Aug 9, 2039formulationUS 11884634
Aug 9, 2039formulationUS 11884634
Aug 9, 2039formulationUS 11884634
Aug 9, 2039formulationUS 11884635
Aug 9, 2039formulationUS 11884635
Aug 9, 2039formulationUS 11884635
Aug 9, 2039formulationUS 11905255
Aug 9, 2039formulationUS 11905255
Aug 9, 2039formulationUS 11905255
Aug 9, 2039formulationUS 12116347
Aug 9, 2039formulationUS 12116347
Aug 9, 2039formulationUS 12116347
Aug 9, 2039formulationUS 12297177
Aug 9, 2039formulationUS 12297177
Aug 9, 2039formulationUS 12297177
Aug 18, 2030compositionUS 77954474.0y
Aug 18, 2030compositionUS 77954474.0y
Aug 18, 2030compositionUS 77954474.0y

FDA exclusivities (6)

Nov 27, 2030ODE-452Orphan Drug (7y)4.3y
Nov 27, 2030ODE*ODE*4.3y
Nov 27, 2030ODE*ODE*4.3y
Nov 27, 2028NCENew Chemical Entity (5y)2.3y
Nov 27, 2028NCENew Chemical Entity (5y)2.3y
Nov 27, 2028NCENew Chemical Entity (5y)2.3y

News(1)

Aura, Schrödinger trim workforces
Follow along as BioSpace tracks job cuts and restructuring initiatives.
biospace · 17h ago

Data sources

openFDA · ClinicalTrials.gov

last refreshed 33m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

nirogacestat hydrobromide

Marketedupdated 3mo ago

by SpringWorks Therapeutics Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 3

all catalysts(3)

approval · 3

Nov 27, 2023

approval

3y ago

OGSIVEO (NIROGACESTAT HYDROBROMIDE) — FDA approval

nirogacestat hydrobromide

OGSIVEO (NIROGACESTAT HYDROBROMIDE) — FDA approval

nirogacestat hydrobromide

OGSIVEO (NIROGACESTAT HYDROBROMIDE) — FDA approval

nirogacestat hydrobromide

→

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 27, 2028

~2.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (84)

May 19, 2043method-of-use (U-3754)US 11872211
May 19, 2043method-of-use (U-3754)US 11872211
May 19, 2043method-of-use (U-3754)US 11872211
May 19, 2043method-of-use (U-3754)US 11925619
May 19, 2043method-of-use (U-3754)US 11925619
May 19, 2043method-of-use (U-3754)US 11925619
May 19, 2043method-of-use (U-3754)US 11925620
May 19, 2043method-of-use (U-3754)US 11925620
May 19, 2043method-of-use (U-3754)US 11925620
May 19, 2043method-of-use (U-3754)US 11938116
May 19, 2043method-of-use (U-3754)US 11938116
May 19, 2043method-of-use (U-3754)US 11938116
May 19, 2043method-of-use (U-3754)US 11951096
May 19, 2043method-of-use (U-3754)US 11951096
May 19, 2043method-of-use (U-3754)US 11951096
May 19, 2043method-of-use (U-3754)US 11957662
May 19, 2043method-of-use (U-3754)US 11957662
May 19, 2043method-of-use (U-3754)US 11957662
May 19, 2043method-of-use (U-3754)US 12011434
May 19, 2043method-of-use (U-3754)US 12011434
May 19, 2043method-of-use (U-3754)US 12011434
May 19, 2043method-of-use (U-3754)US 12011435
May 19, 2043method-of-use (U-3754)US 12011435
May 19, 2043method-of-use (U-3754)US 12011435
May 19, 2043method-of-use (U-3754)US 12036207
May 19, 2043method-of-use (U-3754)US 12036207
May 19, 2043method-of-use (U-3754)US 12036207
May 19, 2043method-of-use (U-3754)US 12138246
May 19, 2043method-of-use (U-3754)US 12138246
May 19, 2043method-of-use (U-3754)US 12138246
Sep 8, 2042formulationUS 11807611
Sep 8, 2042formulationUS 11807611
Sep 8, 2042formulationUS 11807611
Sep 8, 2042formulationUS 11844780
Sep 8, 2042formulationUS 11844780
Sep 8, 2042formulationUS 11844780
Jul 8, 2042formulationUS 11504354
Jul 8, 2042formulationUS 11504354
Jul 8, 2042formulationUS 11504354
Jul 8, 2042formulationUS 11612588
Jul 8, 2042formulationUS 11612588
Jul 8, 2042formulationUS 11612588
Jul 8, 2042formulationUS 12110277
Jul 8, 2042formulationUS 12110277
Jul 8, 2042formulationUS 12110277
Jul 8, 2042formulationUS 12234210
Jul 8, 2042formulationUS 12234210
Jul 8, 2042formulationUS 12234210
Jul 8, 2042formulationUS 12247012
Jul 8, 2042formulationUS 12247012
Jul 8, 2042formulationUS 12247012
Aug 9, 2039compositionUS 10590087
Aug 9, 2039compositionUS 10590087
Aug 9, 2039compositionUS 10590087
Aug 9, 2039compositionUS 10710966
Aug 9, 2039compositionUS 10710966
Aug 9, 2039compositionUS 10710966
Aug 9, 2039compositionUS 10941118
Aug 9, 2039compositionUS 10941118
Aug 9, 2039compositionUS 10941118
Aug 9, 2039formulationUS 11820748
Aug 9, 2039formulationUS 11820748
Aug 9, 2039formulationUS 11820748
Aug 9, 2039compositionUS 11845732
Aug 9, 2039compositionUS 11845732
Aug 9, 2039compositionUS 11845732
Aug 9, 2039formulationUS 11884634
Aug 9, 2039formulationUS 11884634
Aug 9, 2039formulationUS 11884634
Aug 9, 2039formulationUS 11884635
Aug 9, 2039formulationUS 11884635
Aug 9, 2039formulationUS 11884635
Aug 9, 2039formulationUS 11905255
Aug 9, 2039formulationUS 11905255
Aug 9, 2039formulationUS 11905255
Aug 9, 2039formulationUS 12116347
Aug 9, 2039formulationUS 12116347
Aug 9, 2039formulationUS 12116347
Aug 9, 2039formulationUS 12297177
Aug 9, 2039formulationUS 12297177
Aug 9, 2039formulationUS 12297177
Aug 18, 2030compositionUS 77954474.0y
Aug 18, 2030compositionUS 77954474.0y
Aug 18, 2030compositionUS 77954474.0y

FDA exclusivities (6)

Nov 27, 2030ODE-452Orphan Drug (7y)4.3y
Nov 27, 2030ODE*ODE*4.3y
Nov 27, 2030ODE*ODE*4.3y
Nov 27, 2028NCENew Chemical Entity (5y)2.3y
Nov 27, 2028NCENew Chemical Entity (5y)2.3y
Nov 27, 2028NCENew Chemical Entity (5y)2.3y

News(1)

Aura, Schrödinger trim workforces
Follow along as BioSpace tracks job cuts and restructuring initiatives.
biospace · 17h ago

Data sources

openFDA · ClinicalTrials.gov

last refreshed 33m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

nirogacestat hydrobromide

🐶 often sniffed alongside

all catalysts(3)

Patent cliff

patents (84)

FDA exclusivities (6)

News(1)

Report a data issue

comments(0)

nirogacestat hydrobromide

🐶 often sniffed alongside

all catalysts(3)

Patent cliff

patents (84)

FDA exclusivities (6)

News(1)

Report a data issue

comments(0)